Source: Eur Respir J 2014; 44: 1627-1634
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Savale Laurent, Sattler Caroline, Günther Sven, Montani David, Chaumais Marie-Camille, Perrin Swanny, Jaïs Xavier, Seferian Andrei, Jovan Roland, Bulifon Sophie, Parent Florence, Simonneau Gérald, Humbert Marc, Sitbon Olivier. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J 2014; 44: 1627-1634

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary arterial hypertension in patients treated with interferon Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy Source: ERJ Open Res, 7 (1) 00725-2020; 10.1183/23120541.00725-2020 Year: 2021 Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Pulmonary rehabilitation in patients with pulmonary arterial hypertension Source: ERS Course 2017 Year: 2017 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Evaluation of serum cytokines in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with hypercholesterolemia Source: International Congress 2017 – PAH and CTEPH Year: 2017 Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Changing serum cytokines levels in patients with idiopathic pulmonary arterial hypertension treated with bosentan Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Pulmonary hypertension and arterial stiffness in patients with systemic scleroderma Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Treatment of pulmonary hypertension Source: Virtual Congress 2020 – Treatment in pulmonary hypertension Year: 2020 Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Survival in idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary circulation III Year: 2010 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006